Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - sodium nitroprusside -

États-Unis - anglais - NLM (National Library of Medicine)

hainan poly pharm. co., ltd. - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. sodium nitroprusside is indicated for the treatment of acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. - diseases with compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting). - inadequate cerebral circulation or in moribund patients (a.s.a. class 5e) coming to emergency surgery. - patients with congenital (leber’s) optic atrophy or with tobacco amblyopia.   - acute heart failure associated with reduced peripheral vascular resistance. - concomitant use with sildenafil, tadalafil, vardenifil, or riociguat.  risk summary based on animal data and mechanism of action, sodium nitroprussid

États-Unis - anglais - NLM (National Library of Medicine)

exela pharma sciences, llc - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 0.5 mg in 1 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. sodium nitroprusside is indicated for the treatment of acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. risk summary based on animal data and mechanism of action, sodium nitroprusside may lead to cyanide exposure and potential adverse effects in the fetus [see clinical pharmacology (12.3) and clinical considerations] . published post-marketing reports with sodium nitroprusside use in pregnant women are insufficient to inform a drug-associated risk of adverse pregnancy related outcomes [see data] . there were no animal reproduction studies conducted with sodium nitroprusside during pregnancy.  however, there are

États-Unis - anglais - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. sodium nitroprusside is indicated for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. - diseases with compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting). - inadequate cerebral circulation or in moribund patients (a.s.a. class 5e) coming to emergency surgery. - patients with congenital (leber’s) optic atrophy or with tobacco amblyopia. - acute heart failure associated with reduced peripheral vascular resistance. - concomitant use with sildenafil, tadalafil, vardenafil, or riociguat. based on animal data and mechanism of action, sodium nitroprusside may lead to cya

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sodium nitroprusside dihydrate 25 mg/ml - solution for injection - 50 mg/2ml - active: sodium nitroprusside dihydrate 25 mg/ml excipient: water for injection - sodium nitroprusside concentrated injection is indicated for immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.

Canada - anglais - Health Canada

sterimax inc - sodium nitroprusside - solution - 25mg - sodium nitroprusside 25mg - direct vasodilators

Canada - anglais - Health Canada

marcan pharmaceuticals inc - sodium nitroprusside - solution - 25mg - sodium nitroprusside 25mg - direct vasodilators